Neoadjuvant nivolumab plus gemcitabine–cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine–cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial

Authors:

Abstract
No abstract available
Funding Information
  • Bristol-Myers Squibb

This publication has 27 references indexed in Scilit: